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What and How Do Cancer Systems
Biologists Explain?
Anya Plutynski and Marta Bertolaso*y
In this article, we argue, ﬁrst, that there are very different research projects that fall under
the heading of “systems biology of cancer.”While they share some general features, they
differ in their aims and theoretical commitments. Second, we argue that some explana-
tions in systems biology of cancer are concerned with properties of signaling networks
(such as robustness or fragility) and how they may play an important causal role in pat-
terns of vulnerability to cancer. Further, some systems biological explanations are com-
pelling illustrations of how “top-down” and “bottom-up” approaches to the same phe-
nomena may be integrated.
1. Introduction. “Systems biology” has become an extremely popular ﬁeld
of study—one that has attracted the attention of funding agencies and insti-
tutions around the globe. This is especially so in the context of medicine.
Cancer systems biology, for example, is presented as a more “systematic”
approach to such a complex disease. However, those who adopt this label
are not concerned with the same family of questions and do not necessarily
endorse one common set of theoretical commitments or methods.
Our project in this article is to examine what—if anything—is distinctive
about explanations offered in the domain of cancer systems biology. In ser-
vice of this aim, we ﬁrst brieﬂy discuss the historical origins of the ﬁeld. We
follow a twofold classiﬁcation of systems biology approaches, drawing on
O’Malley and Dupré (2005): a “pragmatic” and a “systems theoretical” ap-
proach. Pragmatic approaches are concerned largelywith prediction, or what
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is often described as “translational” medicine: they aim at developing new
prognostic and diagnostic tests and designing targeted interventions. In con-
trast, “systems theoretical” approaches are concerned with identifying gen-
eral principles of systems, such as structural features of regulatory pathways
or signaling networks that play a role in “tipping the balance” toward a can-
cerous phenotype. In addition, one central aim of the latter approach is to
understand features of such systems that enable the evolution of resistance
to treatment.
There is another way of characterizing “systems” approaches, which we
also ﬁnd fruitful (Bruggeman and Westerhoff 2007): a “bottom up” versus
“top down” approach. Many systems biological explanations fall some-
where in the middle. That is, they involve integration of a mechanistic un-
derstanding of cell and molecular processes with “macro-” or “systems level”
approaches. This distinction is helpful in that it illuminates how systems bio-
logical explorations of cancer are often multiscale, building “up” from bio-
chemistry and cell andmolecular biology and, simultaneously,moving “down”
from structural or network models into the realizers of these patterns and their
common features (for similar views, see also Fagan 2012; O’Malley et al.
2014; Green, Fagan, and Jaeger 2015).
2. A Brief History: Systems Biology in Cancer. Many scientists charac-
terize their work as “cancer systems biology.”Not all of them share the same
theoretical commitments or aims. Indeed, given the competitive funding en-
vironment for cancer research, and the rhetorical power of talk of cancer as a
“systems” disease, somemeasure of skepticism is in order regarding the unity
of “cancer systems biology” as a ﬁeld of inquiry. The label’s popularity is in
part a product of institutional and economic forces and in part also a product of
a broader set of transitions in biological sciences, growing out of the expan-
sion of biotechnology, the genomes projects, and the increasing emphasis
on interdisciplinarity in the twenty-ﬁrst century.
One indicator of how a systems approach has been institutionalized can
be found in a National Research Council (2009) report. In July 2008 the Na-
tional Institutes of Health (NIH), National Science Foundation, and Depart-
ment of Energy asked the National Research Council’s Board on Life Sciences
to “examine the current state of biological research in theUnited States and rec-
ommend how best to capitalize on recent technological and scientiﬁc advances
that have allowed biologists to integrate biological research ﬁndings, collect
and interpret vastly increased amounts of data, and predict the behavior of
complex biological systems” (11). The board convened a committee to take
on this assignment. This resulted in the aforementioned report. The commit-
tee made a number of recommendations. First, they encouraged funding re-
search that links engineering, mathematics, computer science, and biology.
Second, they emphasized similarities across biological systems at different
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scales and encouraged identiﬁcation and exploration of common properties
of biological and engineered systems, such as “fragility, robustness, complex-
ity, and organizing principles.” The report led to a new funding program at
the NIH in integrative or systems biology.
Since 2008, institutes for, schools of, and centers for systems biology
have been created at many of the major research institutions in the United
States (Stanford, Harvard, New York University, Columbia, University of
Massachusetts, Washington State, etc.) and internationally (Italy, Germany,
Hungary, France, Denmark, Austria, Switzerland, the United Kingdom, Rus-
sia, India, China, Pakistan, Japan, and Australia). The NIH founded an Inte-
grative Cancer Biology Program,which now funds 12 centers for Cancer Sys-
tems Biology. The stated aims of these programs vary. What, apart from the
label, ties all these programs together? The stated of aims of many of these
institutions, as presented on websites and in papers, include the following
common characteristics:
• All such programs emphasize interdisciplinarity. They host scholars
from diverse disciplines, such as biostatistics, computational biology,
engineering, computer science, genetics and genomics, and cell and mo-
lecular biology. They also emphasize interdisciplinary methods and,
particularly, development and use of new technology, for example, high-
throughput experimental platform technologies.
• They are data driven, often involving “big data.” In particular, the rise
of the cancer genomics, epigenomics, proteomics, and transcriptomics
projects has led to a vast amount of information that needs to be curated,
organized, and mined to generate network models, for instance, docu-
menting the co-occurrence of mutations or gene products in various can-
cer subtypes. These are collected and collated by national and inter-
national organizations, such as the Cancer Genome Database, or the
Cancer Genome Atlas.
• They are concerned with modeling: simulation models, mathematical
models of various sorts, network models, or multiscale models (Deis-
boeck et al. 2011). Such models may be used to generate hypotheses,
integrate data, or simply provide visual representations of otherwise
overwhelming amounts of statistical data, such as representations of
genes frequently mutated in this or that cancer type or dynamic spatial
models of vast interconnected cell signaling pathways associated with
outcomes and processes in cancer at very different scales.
The vast majority of this research is concerned with diagnosis and treat-
ment: developing “targeted” drugs or better classifying cancer types and
subtypes so as to arrive at more precise, or “personalized,” therapy. This
work might be characterized as more “pragmatic” in character, and it uses
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data-driven methods that, for instance, draw on thousands of samples from
tumor biopsies and sequences of these samples to generate databases of can-
cer biomarkers (genomic, epigenomic, transcriptomic, proteomic), in ser-
vice of better predictions about the behavior of different subtypes of cancer
or likely drug targets. Much of this work uses machine learning, bioinfor-
matics, and network modeling.
In contrast, some work in cancer systems biology is less focused on the
pragmatic applications of the research than on arriving at some general the-
oretical principles about the dynamics and topography of complex systems,
taking cancer as a case in point. This distinction nicely coincides with the
more general distinction made by O’Malley and Dupré: “Systems biology
is best understood as consisting of two streams. One, which we shall call
‘pragmatic systems biology’, emphasizes large-scale molecular interactions;
the other, which we shall refer to as ‘systems-theoretic biology’, emphasizes
system principles” (2005, 1270). Some systems theoretical biologists argue
that there are common structural features of networks that both explain and
predict cancers’ behaviors. Such structural features are sometimes called
“motifs.” In general, systems theoretical biologists are concerned with how
general features of networks explain or predict the behavior of complex bio-
logical systems. More precisely, in this ﬁeld any network property (e.g.,
network robustness or degree distribution) is both an explanandum and
explanans (cf. Huneman 2017).
For example, some systems biologists have argued that there may be dis-
tinctive structural features of networks of signaling molecules controlling
cell birth and death that make us far less vulnerable to cancer than we might
otherwise be. Scale-free networks are networks that have a degree distribu-
tion that follows a power law, where a network’s degree distribution is the
network-wide proportion of edges connected to k other nodes. So, scale-free
networks have many nodes connected to only one or a few other nodes and
only a few nodes connected to many other nodes (hubs). Scale-free networks
have a number of core properties, what systems biologists call “distributed
robustness”: “many parts of a system contribute to system function, but all of
these parts have different roles. When one part fails or is changed through
mutations, the system can compensate for this failure, but not because a
‘back-up’ redundant part takes over the failed part’s role” (Wagner 2005,
177). Robust systems maintain function despite perturbation, where pertur-
bation might mean elimination or disruption of the activity of nodes.
In scale-free networks, one can eliminate many such nodes without dis-
rupting function. However, if one disrupts several hubs, then function is de-
stabilized. Thus, scale-free networks are “robust” generally but are vulner-
able to disruption of highly connected nodes. All things considered, then,
scale-free networks may be considered to be relatively robust to insult, in
comparison to randomly distributed networks. Once several hubs are af-
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fected, they can quickly collapse. Indeed, this may be what we see in cancer.
In the case of cancer, there are core “drivers,” or hubs, that affect many
downstream regulatory functions in the cell, including but not limited to ad-
vancing the cell cycle (and thus initiating or halting cell division), initiating
cell death, and transferring such signals from outside to inside the cell.
Some of the genes most commonly affected in cancer are hubs in net-
works of signaling cascades that affect cell birth and death. The scale-free
network structure of these signaling pathways may explain (in part) how
we are vulnerable to cancer, as well as why we do not get cancer more often.
When many hubs are disrupted, there is destabilization of function; but there
is also robustness to insult, insofar as scale-free structures prevent disruption
of cell functions (Alon 2007; Barillot et al. 2012).
To be sure, much of this discussion is very theoretical and difﬁcult to es-
tablish empirically. In part for these reasons, not everyone is optimistic about
this general project and method. Robert Weinberg, one of the most accom-
plished contributors to cancer research, has expressed skepticism about the
ambitions of systems biology: “The currently embraced notion is that a com-
plex system can only be understood if all of its moving parts are analyzed in
one sweeping overview. . . . The data that we now generate overwhelm our
abilities of interpretation, and the attempts of the new discipline of ‘systems
biology’ to address this shortfall have to date produced few insights into can-
cer biology beyond those revealed by simple, homegrown intuition. The
coupling between observational data and biological insight is frayed if not
broken” (Weinberg 2014, 270). Is there good reason for Weinberg’s skep-
ticism of systems biology? Belowwe consider some examples of systems bi-
ological approaches to explaining various features of cancer. Our goal is to say
what is distinctive, if anything, about such approaches, as well as to speak to
whether Weinberg’s skepticism about the project is warranted.
3. Examples: Network Robustness and Network Topology. Let us turn
to some successful and representative examples of systems biology of can-
cer. One project central to cancer systems biology is mapping out networks
of biochemical pathways that play important roles in behaviors typical of
cancer cells. For instance, one way in which cancer cells develop the ability
to grow without limit is via autocrine signaling (self-signaling loops), where
mitogens (molecules that activate growth) are produced excessively, or bound
excessively. The products of many so-called oncogenes, such as src, act as a
mitogen. The ERBB (also known asHER) family or epidermal growth factor
receptor (EGFR) family consists of four structurally related receptor tyrosine
kinases—receptors for signaling molecules that play a role in cell division.
They are part of a complex signaling network that is essential in growth and
development. They also play a role in cancer.
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Excessive EGFR/ERBB signaling is common in a wide variety of solid
tumors. Ampliﬁcation of EGFR expression can be found in 20%–30% of
metastatic breast lesions (Slamon et al. 1987) and in small fractions of sev-
eral types of carcinoma (e.g., head and neck cancer and brain tumors; Ek-
strand et al. 1991). The ERBB family is a classic case of pathway degener-
ation, which occurs when genes are duplicated in evolution, and these
duplicated genes acquire some new functional specializations but conserve
the original function in part. So, in this way, the associated function is robust:
redundancy enables the system as a whole to perform the same function.
This is the case for ERBB.
The robustness of this gene family in part explains why therapies target-
ing EGFR are thwarted: coactivation of alternate kinases that have partial
overlap with EGFR can compensate when one particular subpart is compro-
mised. In other words, the robustness of the network in part explains both
the signiﬁcance of EGFR disruption in cancer and the evolution of chemo-
therapy resistance to drugs that target the ERBB family. The robustness of
the network in the latter case constitutes the explanans, rather than the ex-
planandum. Of course, the way in which an appeal to the robust structure
of the network does explanatory work depends on how we specify the ex-
planandum (cf. Craver 2016).
When determining what roles ERBB plays in cancer, we might ask very
different questions:
• What is the function of this complex and how is its mechanistic basis
realized?
• How does disruption of that function play a role in cancer progression?
• What features of this signaling complex (and its relation to other sig-
naling systems in the cell) make its disruption particularly likely to
lead to cancer? Is this part of a larger network?
• What is the spatial organization of this network, and how does this or-
ganization contribute to its dynamic patterns of expression or regula-
tory functions or role in dysfunctional outcomes?
• How do drugs that target the ERBB family fail?
• Are drugs that target one or more members of this family likely to fail,
and why?
• Are there speciﬁc structural features of the network that make drugs
likely to fail?
In elaborating answers to the ﬁrst two of these questions, we might appeal to
mechanistic information. The last four questions, however, require appeal to
more general systems theory. Answering all such questions will require in-
tegration of information from cell and molecular biology, systems theory,
gene regulatory network modeling, computational biology, and evolution-
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ary and developmental biology. Cell and molecular biology can inform us
about ERBB functions and their mechanistic realization. Such explanations
are causal and functional explanations. In contrast, systems theoretical ap-
proaches can help us illuminate relevant features of ERBB network struc-
ture, which may contribute to its robustness, its role in our vulnerability to
cancer, and its role in the evolution of chemotherapy resistance. In this
way, systems approaches bridge the gap between more reductive, mechanis-
tic approaches to cancer and evolutionary developmental biology. The latter
approaches help explain why certain kinds of circuitry and network struc-
tures are so common, across a variety of species (see, e.g., Levine and Da-
vidson 2005) and how they come to play a role in cancer.
Cell division in healthy tissue is usually tightly regulated. This is trace-
able to our evolutionary history. When the ﬁrst multicellular organisms
evolved, cells needed to acquire the capacity to cooperate—that is, limit
growth, share resources, and be responsive to intercellular signals. As Amit,
Wides, and Yarden (2007, 1) put it, “To precisely coordinate and integrate
cellular decisions such as proliferation, differentiation and apoptosis, meta-
zoans developed a set of information relay systems.”Disruption of such cell
signaling pathways, particularly associated with growth, is one common fea-
ture, or hallmark, of cancer cells. Many of the same hub genes are associated
with several of these pathways—they are pleiotropic in their effects (see,
e.g.,Weinberg 2013, chap. 6, for discussion). Gene regulatory networkmod-
elers call genes and associated subcircuits that play important roles in lock-
ing down key functions in the cell “kernels” (Levine and Davidson 2005).
Such hubs play an important functional and structural role in cancer pro-
gression. The structure of such networks helps explain consistent patterns in
the dynamics of cancer progression, as well as how and why some cancers
are either more or less resilient to insult (i.e., chemotherapy). Taking a “net-
work perspective” on ERBB helps characterize this “Achilles heel” in can-
cer; that is, it helps explain how and why ERBB is so frequently disrupted
and so difﬁcult to target:
The ERBB family actually represents a bona ﬁde biological network that
obeys the principles of network theories. Interestingly, biological networks
tend to adopt a scale-free architecture. . . . The increased stability of such
networks comes with a cost that translates into fragility: essential hubs
might be ‘Achilles heels’. . . . The ERBB system incorporates many net-
work features, such as modularity and multiple control loops. As for other
networks, the ERBB network displays two steady states (bistability), and
ligands transiently switch it fromOFF to ON. Several oncogenic mutations
bias a prolonged ON state. For example, by favoring ERBB2-containing
heterodimers and escaping negative feedback regulation, pathological
ERBB2 ampliﬁcation creates a hub that enhances signaling while exposing
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pharmacological susceptibilities. . . . Network plasticity and robustness are
manifested repeatedly following drug intervention, as reﬂected by the emer-
gence of drug resistance. . . . Biological networks show fragility in the face
of simultaneous perturbations (for example, combination therapy). Another
uncommon perturbation is exempliﬁed by monoclonal-antibody-mediated
recruitment of the immune system. Careful analyses of the network may re-
veal other tumor-speciﬁc vulnerabilities and addictions that are amenable for
pharmacological interventions. (Yarden and Pines 2012, 560).
In sum, what explains the ERBB complex’s unique role in cancer, and ro-
bustness to single agent chemotherapy, is the structure of the network of
which it is a part.
The ERBB complex thus provides an illustration of several general prin-
ciples in systems theory. Namely, the very properties of cell signaling path-
ways that enable robustness and evolvability (modularity, scale-free struc-
ture) can become a site of vulnerability, and redundancy can both be an
advantage and pose a challenge in treatment contexts. Systems biologists
identify common elements of such networks and the roles they play in var-
ious stages of progression in cancer. They ﬁrst identify associations between
particular genes mutated in cancer and then build a network model, a repre-
sentation of both the organizational structure and dynamics of gene expres-
sion over time, as a tumor progresses. For instance, Sadeghi et al. (2016) dis-
tinguished the most important transcription factors affected in primary
prostate tumor samples (HOXD10, BCL2, and PGR) from those playing a
central role in the metastatic state (STAT3, JUN, and JUNB). Before their
analysis, a number of genes had been reported as involved in prostate cancer
progression, being down regulated in some studies and overexpressed in
other studies (see also Bo and Tucker 2015; Nazarieh et al. 2016). What
the network model achieved was identiﬁcation of central hubs and likewise
targets for intervention at different stages in progression.
More generally, molecular systemic models of the cell connect molecular
agents, growth factors, and cytokines into an endogenous molecular-cellular
network characterized by these distinctive interactions and associated vul-
nerabilities. The topological features of these complex networks can be used
to model the dynamics of progression typical in cancer. A nonlinear system
is a system in which the change of the output is not proportional to the
change of the input and may appear chaotic. Complex networks have mul-
tiple stable states (where a state is a pattern of activation of elements and var-
iables). These stable states are called “attractors,” which reside within a
“functional landscape” of the network. The state space is the total set of pos-
sible network states, plus the transitions and trajectories between them. The
particular architecture of the network determines how movement through
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the state space is constrained. In other words, the network structure of such
systems helps us identify how and when mutations to sets of genes, such as
the ERBB family, are likely to lead to cancer.
According to some proponents of systems theory, changes in the cellular
phenotype underlying progression to metastasis may result from exactly
these transitions within entire genome-wide gene regulatory networks. Mu-
tations can lead to molecular signals that contribute to the shift of the sys-
tem toward an attractor (eventuating in a tumor; Huang and Ingber 2007;
Huang, Ernberg, and Kauffman 2009). Cancer, from this perspective, is
seen as a robust state of the endogenous cellular network (Ao et al. 2008).
That is, our vulnerability to cancer is an intrinsic property of the cells—one
inherited from the developmental and evolutionary history of the organism.
For example, the transition from mesenchyme to epithelial cells is one that
all epithelial cells undergo during development; cancer shows that the capac-
ity to “return” to this phenotype is retained. An epithelial-mesenchymal tran-
sition encompasses, in a broad sense, all changes in cell morphology from
epithelioid to mesenchymal correlated to the increased motility of cancer
cell lines. In the attractor landscape perspective, the mesenchyme pheno-
type is considered a distinct cellular program, a “stable state,” to which can-
cer cells return by reacquiring those same gene expression proﬁles typical of
earlier developmental stages. To the extent that cells have this potential, these
“embryonic” attractors remain present in adulthood (Laforge et al. 2005) and
effectively function as “tumor attractors” (Fogarty, Kessler, and Wechsler-
Reya 2005). In this way, ontogeny provides oncogenesis with a starting point
(Huang and Ingber 2007; Ingber 2008). In other words, from a systems per-
spective, we may view the malignant phenotype as one of the states poten-
tially existing in the cell. Preexisting attractors explain the easewithwhich ran-
dom mutations can quickly produce features typical of earlier developmental
stages.
There are several such “endogenous” networks—networks that are typi-
cal or normally activated in healthy or developing tissue—that may be acti-
vated in cancer. For instance, tumors co-opt the wound-healing response in
order to induce the stroma they require for maintenance and growth. As
Dvorak originally suggested (1986), cancers are “wounds that do not heal.”
Tumors share properties with healing wounds. Vascular permeability factor
(VPF, subsequently renamed vascular endothelial growth factor [VEGF]) is
a tumor product. The sequence of events associated with cancer progression
(increased vascular permeability; extravasation of plasma, ﬁbrinogen, and
other plasma proteins; activation of the clotting system outside the vascular
system; etc.) also takes place in a variety of important inﬂammatory diseases
that involve cellular immunity (Dvorak 2015). One can model such cases as
an example of a network of inter- and intracellular signaling, which achieves
a stable state, via production of gradients of growth factors, modulation of
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the permeability of membranes, and generation of new structures (in this
case, angiogenesis).
Networks such as this are sensitive to critical thresholds. According to the
Autostabilization-Selection Model (Laforge et al. 2005), a gradual accumu-
lation of many small alterations in signaling molecules within and between
cells can lead to a shift in an ordinarily stable state. Laforge’s model incor-
porates experimental data from gene expression studies and traces the shift
in stability to the modulation of the concentration of transcriptional regula-
tors in the cell in relation to differentiation. It also takes into account simi-
larities with models pertaining to the theories of morphogenesis. On this
model, the process of cancer progression enacts, in several respects, a rever-
sal of morphological development. Tissue formation is not the result of a sin-
gle type of cellular change or speciﬁc mechanistic interaction but involves
multiple complementary molecules that exert various effects on tissue orga-
nization. An imbalance in these factors can lead to tissue disorganization and
invasive growth.
Several systems biological explanations are bottom-up as much as they
are top-down. These two consolidated, conceptually different approaches
(Van Laere, Dirix, and Vermeulen 2016) thus ﬁnd integration in cancer sys-
tems biology. “Bottom-up” approaches reveal upstream signaling pathways
based on gene expression proﬁle changes. “Top-down” approaches translate
gene expression changes, or any other molecular proﬁle, into downstream
biological responses. Top-down gene clustering can assist in ﬁnding sets
of coregulated genes. “Network enrichment” is a technique that establishes
which pathways and processes are relevant to a given outcome and how they
are associated with each other in the network. Networks may also be built
from molecular data (this is “network inference”; Bansal et al. 2007). The
bottom-up approach is better suited for identifying pathways, whereas the
top-down approach is more appropriate to evaluate biological processes,
functional and dysfunctional (Van Laere et al. 2016).
For example, a recent study inferred a set of 33 transcription factors as-
sociated with gene signatures of several known phenotypes involved in
small cell lung cancer (SCLC; Udyavar et al. 2017). Udyavar et al. built a
network simulation, incorporating all known involved pathways. Simula-
tions predicted that the network will settle into attractors, or transcription
factors expression patterns, that correlate with phenotypes. The strong cor-
relation with observed outcomes suggested that transcription factors net-
work dynamics underlie the emergence of heterogeneous SCLC pheno-
types. The model also predicted a hybrid phenotype that was conﬁrmed by
experimental activity (with the ﬂow cytometry technique). This explained
several clinical observations, especially treatment failures, convergence
under treatment of different tumor cells on a single phenotype, and wild
phenotypic heterogeneity.
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More researchers are starting to combine top-down and bottom-up ap-
proaches to build systems biological explanations of cancer phenomena. Ac-
cording to Udyavar et al., these approaches “should be generally useful in
uncovering underlying mechanisms” (2017, 1072). Thus, we can see how
Weinberg’s skepticism might be addressed: the kinds of questions systems
biologists ask, and the strategies by which they answer such questions,
are different from those typical in the cell and molecular biology of cancer
but complementary to them. Such approaches involve drawing on vast
amounts of data, building network models, and generating hypotheses about
mechanisms. So, this different approach asks (and answers) a different array
of questions about cancer, focusing less on uncovering speciﬁc mechanisms
than on dynamic structural relationships of networks of signaling molecules
and genes associated with cancer progression.
4. The Upshot. What then is distinctive about these explanatory projects?
There is nothing here that contradicts the idea that many biological explana-
tions concern the identiﬁcation and decomposition of mechanisms into their
parts and processes (see, e.g., Brigandt, Green, and O’Malley 2017). How-
ever, systems biological approaches identify different target explananda
than is typical of mechanistic explanations and draw on different theoretical
frameworks and methods. They are concerned with general patterns of sta-
bility and instability in the dynamics of cancer progression. This requires
placing cell intrinsic mechanisms associated with cancer initiation and pro-
gression in a larger context, at a variety of temporal and spatial scales, from
the cell-signaling networks active in wound healing to evolutionary and de-
velopmental history. In this way, they integrate top-down and bottom-up
perspectives on the same phenomena.
For instance, we argued that the structural features of certain networks ex-
plain both their resistance to and subjection to insult. This is not at odds with
mechanistic description but both supplementary to and more comprehensive
than mechanistic explanations, in that such accounts contextualize the role(s)
of mechanisms in a larger system and sometimes show them to be instances of
more general patterns. As Brigandt et al. argue, “what makes research . . . dis-
tinctively systems-biological stems from the fact that large networks are
screened to . . . reveal both common and uncommon elements of biological
design. . . . Abstract organizational schemes . . . and design principles, tran-
scend the organization of a single mechanism, and even a single species”
(2017, 365).
We have extended this analysis into the realm of cancer research.We have
argued ﬁrst that cancer systems biology is a kludge; there are many different
research projects that fall under this heading. While they share many fea-
tures, they differ in their central aims and theoretical commitments. We ar-
gued that what is distinctive about explanations in cancer systems biology is
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that at least some aspire to offer top-down, structural explanations that ap-
peal to the robust features of networks. In contrast, others appear to integrate
top-down and bottom-up approaches.
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